Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sibeprenlimab in Immunoglobulin A Nephropathy
NCT05248646Phase 3Active, not recruiting
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Mar 2022
- Primary completion
- May 2026
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 31
01
Overview
A Phase 3 trial of sibeprenlimab in immunoglobulin A nephropathy (IgAN), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Mar 2022; status: active, not recruiting.
02
Drugs
sibeprenlimab
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05248646.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05248646.